| Primary |
| Hiv Infection |
17.1% |
| Cytomegalovirus Infection |
14.5% |
| Encephalitis Cytomegalovirus |
7.0% |
| Cytomegalovirus Chorioretinitis |
6.5% |
| Pyrexia |
6.5% |
| Infection Prophylaxis |
5.7% |
| Prophylaxis Against Gastrointestinal Ulcer |
5.2% |
| Pneumocystis Jiroveci Pneumonia |
4.4% |
| Opportunistic Infection Prophylaxis |
4.2% |
| Ureteral Stent Insertion |
3.9% |
| Ureteral Stent Removal |
3.9% |
| Infection |
2.9% |
| Lymphoma |
2.6% |
| Prophylaxis Against Graft Versus Host Disease |
2.6% |
| Cytomegalovirus Viraemia |
2.3% |
| Oral Candidiasis |
2.3% |
| Antifungal Prophylaxis |
2.1% |
| Insomnia |
2.1% |
| Leukopenia |
2.1% |
| Oesophageal Candidiasis |
2.1% |
|
| Shock |
9.1% |
| Pulmonary Alveolar Haemorrhage |
7.8% |
| Pancytopenia |
6.5% |
| Renal Failure Acute |
6.5% |
| Renal Impairment |
6.5% |
| Vomiting |
6.5% |
| Hypercalcaemia |
5.2% |
| Interstitial Lung Disease |
5.2% |
| Renal Tubular Disorder |
5.2% |
| Cerebral Haemorrhage |
3.9% |
| Delirium |
3.9% |
| Renal Failure |
3.9% |
| Respiratory Failure |
3.9% |
| Status Epilepticus |
3.9% |
| Tubulointerstitial Nephritis |
3.9% |
| Uveitis |
3.9% |
| Vision Blurred |
3.9% |
| Visual Acuity Reduced |
3.9% |
| Visual Impairment |
3.9% |
| Aids Encephalopathy |
2.6% |
|
| Secondary |
| Hiv Infection |
24.5% |
| Product Used For Unknown Indication |
16.5% |
| Encephalitis Cytomegalovirus |
7.0% |
| Infection Prophylaxis |
6.5% |
| Opportunistic Infection Prophylaxis |
4.5% |
| Prophylaxis Against Gastrointestinal Ulcer |
4.3% |
| Antifungal Prophylaxis |
3.5% |
| Cytomegalovirus Chorioretinitis |
3.1% |
| Pyrexia |
3.1% |
| Drug Eruption |
2.7% |
| Cytomegalovirus Infection |
2.6% |
| Pneumocystis Jiroveci Pneumonia |
2.6% |
| Prophylaxis |
2.6% |
| Cytomegalovirus Enterocolitis |
2.5% |
| Fluid Replacement |
2.5% |
| Drug Use For Unknown Indication |
2.4% |
| Sedation |
2.4% |
| Antibiotic Prophylaxis |
2.3% |
| Oesophageal Candidiasis |
2.3% |
| Leukopenia |
2.2% |
|
| Uveitis |
21.5% |
| Shock |
18.7% |
| Pancytopenia |
7.3% |
| Toxic Epidermal Necrolysis |
7.3% |
| Staphylococcal Sepsis |
6.8% |
| Hyponatraemia |
5.0% |
| Streptococcal Infection |
4.1% |
| Vomiting |
4.1% |
| Renal Failure Acute |
3.2% |
| Renal Impairment |
3.2% |
| Aids Encephalopathy |
2.7% |
| Pulmonary Alveolar Haemorrhage |
2.7% |
| Cytomegalovirus Chorioretinitis |
2.3% |
| Respiratory Failure |
2.3% |
| Mental Status Changes |
1.8% |
| Bone Marrow Failure |
1.4% |
| Cerebral Haemorrhage |
1.4% |
| Hallucination |
1.4% |
| Paraesthesia |
1.4% |
| Sepsis |
1.4% |
|
| Concomitant |
| Drug Use For Unknown Indication |
18.8% |
| Hiv Infection |
14.6% |
| Infection Prophylaxis |
9.3% |
| Product Used For Unknown Indication |
7.4% |
| Cytomegalovirus Infection |
5.9% |
| Prophylaxis |
5.7% |
| Immunosuppression |
5.6% |
| Stem Cell Transplant |
5.3% |
| Prophylaxis Against Graft Versus Host Disease |
4.1% |
| Kaposi's Sarcoma Aids Related |
3.2% |
| Acute Graft Versus Host Disease |
2.4% |
| Acute Myeloid Leukaemia |
2.3% |
| Aspergillosis |
2.3% |
| Chronic Myeloid Leukaemia |
2.3% |
| Bone Marrow Transplant |
2.1% |
| Non-hodgkin's Lymphoma |
2.1% |
| Febrile Neutropenia |
1.8% |
| Hypertension |
1.8% |
| Immunosuppressant Drug Therapy |
1.6% |
| Bone Marrow Conditioning Regimen |
1.5% |
|
| Thrombotic Microangiopathy |
12.8% |
| White Blood Cell Count Decreased |
11.0% |
| Pneumonia Cytomegaloviral |
8.3% |
| Staphylococcal Sepsis |
7.3% |
| Respiratory Failure |
6.4% |
| Shock |
6.4% |
| Platelet Count Decreased |
5.5% |
| Pancytopenia |
4.6% |
| Pyrexia |
4.6% |
| Septic Shock |
4.6% |
| Rash Generalised |
3.7% |
| Thrombocytopenia |
3.7% |
| Upper Gastrointestinal Haemorrhage |
3.7% |
| Venoocclusive Liver Disease |
3.7% |
| Bone Marrow Failure |
2.8% |
| Cystitis Haemorrhagic |
2.8% |
| Death |
2.8% |
| Arrhythmia |
1.8% |
| Brain Stem Haemorrhage |
1.8% |
| Bronchopulmonary Aspergillosis |
1.8% |
|
